BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Rong Pan, Han Liu, Zhenshu Xu
Abstract
B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.
Topics & Concepts
MedicineMultiple myelomaHematologyInternal medicineOncologyMedical physicsMultiple Myeloma Research and TreatmentsCAR-T cell therapy researchProtein Degradation and Inhibitors